The trial’s primary efficacy endpoint is AF burden, which refers to the percentage of time a participant is in AF.

-- EUR35 million Series C funding to accelerate the clinical and industrial development of FlowMaker (R) -- EUR48 million in grants from the IPCEI Tech4Cure program to structure the European Active ...

I spoke with neuroscientists from an Incheon, Korea-based startup that's looking to minimize the symptoms of epilepsy or Parkinson's disease.

Senseonics Holdings, Inc. SENS recently reached an important commercialization milestone with the launch of its Eversense 365 ...

The commercial launch of the integrated products provides people with type 1 diabetes a new level of flexibility and personalization in their diabetes management. Pairing twiist™ with Senseonics’ ...

Resonetics said the deal combines its "comprehensive implantable battery technologies with advanced pulse generator ...

Implantable brain devices introduce a new and significantly more complex class of cybersecurity risk and critical privacy ...

The implantable lens maker said it would remain a stand-alone company after its shareholders turned down Alcon’s $1.6 billion ...

Researchers at UCLA have developed a small sponge that can be implanted next to a tumor to help the body fight it. In tests in mice, the devices induced remission, prevented growth and spread of ...

Series C funding to accelerate the clinical and industrial development of FlowMaker®€48 million in grants from the IPCEI Tech4Cure program to structure the European Active Implantable Medical Devices ...